About SynGen
SynGen is a company based in Sacramento (United States) founded in 2009 was acquired by Cesca Therapeutics in July 2017. SynGen has raised $16.81 million across 14 funding rounds from investors including GE Capital, Cesca Therapeutics and Bay City Capital. SynGen operates in a competitive market with competitors including NanoCellect Biomedical, ThinkCyte, Hemotune, Singulex and Cell Microsystems, among others.
- Headquarter Sacramento, United States
- SectorsHealthcare
- Email••••••••
- Website syngeninc.com/en
- Social LinkedIn
- Acquired by Cesca Therapeutics (Jul 2017)
- Total Equity Funding$16.81M (USD)
in 14 rounds
- Latest Funding Round$500K (USD), Series A
Apr 2017
- InvestorsGE Capital
& 2 more
- Acquired byCesca Therapeutics
(Jul 2017)
Funding Insights of SynGen
SynGen has successfully raised a total of $16.81M across 14 strategic funding rounds. The most recent funding activity was a Series A round of $500 thousand completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.81M
- Total Rounds 14
- Last Round Series A — $500,000
- First Round $5M
(Apr 2012)
- Investors Count 2
Latest 10 of 14 funding rounds of SynGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $500,000 | Series A | – | – | – |
| Mar 2017 | $500,000 | Series A | – | – | – |
| Feb 2017 | $500,000 | Series A | – | – | – |
| Jan 2017 | $500,000 | Series A | – | – | – |
| Nov 2016 | $1M | Series A | – | – | – |
| Jul 2016 | $1M | Series A | – | – | – |
| May 2016 | $1.56M | Series A | – | – | – |
| Feb 2016 | $2M | Debt – Conventional | – | – | – |
| Jun 2015 | $2.25M | Series A | – | – | – |
| Oct 2014 | – | Series A | – | – |
3 investors in total: 3 institutional.
Investors in SynGen
SynGen has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include GE Capital, Cesca Therapeutics and Bay City Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | – | baycitycapital.com | San Francisco, United States | |
Commercial aircraft and equipment leasing and lending services are provided. | 1932 | gecapital.com | United States | |
Cell-based therapeutics are developed for regenerative medicine applications. | 1986 | cescatherapeutics.com | Rancho Cordova, United States |
Investor details for SynGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SynGen
4 dated milestones of SynGen across 8 years, from founding to its latest funding, stage changes and deals.
- Founded SynGen is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series A, of $500K.
- Exit Acquired by Cesca Therapeutics.
Competitors of SynGen
SynGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NanoCellect Biomedical, ThinkCyte, Hemotune, Singulex and Cell Microsystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanocellect.com | 2009 | San Diego, United States | $78.15M | 84 | Develops flow cytometry and cell sorting technology | |
| thinkcyte.com | 2016 | Bunkyo, Japan | $83.18M | – | Cell analysis and sorting technologies are developed with AI integration. | |
| hemotune.ch | 2017 | Zurich, Switzerland | $28.86M | – | Developer of a device for blood purification | |
| singulex.com | 1997 | Alameda, United States | $140.94M | 236 | Single-molecule counting technology is developed for cardiovascular biomarker detection. | |
| cellmicrosystems.com | 2009 | Durham, United States | $19.1M | – | Developer of a technology to isolate and recover single cells for molecular analysis | |
| siliconbiosystems.com | 1999 | Bologna, Italy | $25.53M | – | Lab-on-a-chip technologies for miniaturized cell-biology testing are developed. | |
| extheramedical.com | 2007 | Berkeley, United States | $54.59M | 23 | Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | |
| cytopherx.com | 1994 | Ann Arbor, United States | $47.69M | – | Cytopheresis systems for inflammatory conditions | |
| medcurainc.com | 2019 | United States | $87.35M | – | Developer of the device for controlling bleeding | |
| immunicon.com | 1983 | Bryn Athyn, United States | $75.35M | – | Cell and molecular-based diagnostics for cancer management are developed. |
Detailed competitors of SynGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SynGen
The website of SynGen (syngeninc.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 5.2% vs previous month
Latest news on Syngen
Complete news archive for SynGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SynGen
10 companies that operate in the same segment as SynGen (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SynGen
SynGen was founded in 2009 and raised its 1st funding round 3 years after it was founded.
SynGen is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
SynGen is a funded company, having raised a total of $16.81M across 14 funding rounds to date.
SynGen develops cell separation tools and accessories, applying design to aid regenerative medicine workflows. SynGen design and manufacture products that focus on improving recovery of target cells, depletion of contaminating cells, efficiency and operator ease of use. Also, reduces time for the development of therapeutic products.
SynGen's top competitors include NanoCellect Biomedical, ThinkCyte and Silicon Biosystems.
SynGen has 3 investors. Key investors include GE Capital, Cesca Therapeutics, and Bay City Capital.
Yes. SynGen was acquired by Cesca Therapeutics in July 2017.